Less than a week after Clovis Oncology Inc.'s Rubraca became the first PARP inhibitor approved for prostate cancer, AstraZeneca PLC and Merck & Co. Inc.'s class leader Lynparza has become the second, and the one observers expect to dominate the market.
The US Food and Drug Administration has approved Lynparza (olaparib) for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

